|
End-of-day quote
Pakistan S.E.
2026-09-10
|
5-day change | 1st Jan Change | ||
| 305.50 PKR | -2.50% |
|
-6.20% | -21.62% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 36.66B | 41.84B | 49.66B | 61.19B | 65.9B | |||||
Total Assets | 30.46B | 35.54B | 38.13B | 45.06B | 50.68B | |||||
Interest Expense | -5.43M | -5.37M | -6.52M | -19.28M | -43.12M | |||||
Income Tax Expense | 2.07B | 2.64B | 1.64B | 3.94B | 6.66B | |||||
CAPEX | -1.3B | -1.53B | -1.65B | -2.78B | -2.58B | |||||
EBT | 7.42B | 5.11B | 2.18B | 10.48B | 16.68B | |||||
Gross Profit | 9.74B | 7.28B | 3.5B | 15.39B | 24.38B | |||||
D&A | 775M | 823M | 932M | 1.14B | 1.37B | |||||
Operating Income | 7.59B | 5.82B | 2.24B | 10.79B | 16.85B | |||||
Net Income | 5.35B | 2.46B | 534M | 6.54B | 10.03B | |||||
Total Assets | - | - | - | - | - |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pakistan | 38.12B | 44.27B | 51.74B | 62.22B | 66.44B | |||||
| - | - | - | - | 13.46M | ||||||
Unallocated Commissions, Returns and Discounts | - | - | - | -417M | 98.99M | |||||
| - | - | - | - | -655M | ||||||
Export | 28.88M | 26.46M | - | 15.86M | 13.46M | |||||
| - | - | - | - | 98.99M | ||||||
Unallocated | -1.49B | -2.45B | -2.08B | - | - | |||||
Unallocated Sales Tax | - | - | - | -629M | -655M | |||||
| - | - | - | - | 66.44B |
- Stock Market
- Stocks
- GLAXO Stock
- Financials GlaxoSmithKline Pakistan Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
